Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc. Common Stock (BCAX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bcax · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Bicara Therapeutics Inc. Common Stock (BCAX) measures how much investors pay for each dollar of the company's trailing earnings. BCAX's current PE ratio of N/A is calculated by dividing its stock price of $20.04 by its TTM earnings per share of -$2.59.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2022 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Bicara Therapeutics Inc. Common StockYou BCAX | $1.1B | N/A | — | -$2.59 |
 EyePoint Pharmaceuticals, Inc. EYPT | $963M | N/A | — | -$3.17 |
 Fortrea Holdings Inc. FTRE | $1.6B | N/A | — | -$10.81 |
 Kura Oncology, Inc. KURA | $768M | N/A | — | -$3.18 |
 Maravai LifeSciences Holdings, Inc. MRVI | $1.4B | N/A | — | -$0.90 |
 Phathom Pharmaceuticals, Inc. PHAT | $792M | N/A | — | -$3.03 |
 Prime Medicine, Inc. PRME | $539M | N/A | — | -$1.35 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.52 | — | |
2024-12-31 FY2024 | — | $-1.25 | — | |
2023-12-31 FY2023 | — | $-1.00 | — | |
2022-12-31 FY2022 | — | $-0.73 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Bicara Therapeutics Inc. Common Stock (BCAX) measures how much investors pay for each dollar of the company's trailing earnings. BCAX's current PE ratio of N/A is calculated by dividing its stock price of $20.04 by its TTM earnings per share of -$2.59.
Frequently asked questions
BCAX pe ratio · 6 questionsBCAX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $20.04 and TTM EPS of -$2.59. Data sourced from Financial Modeling Prep via BCAX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bicara Therapeutics Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08